These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 17559750)
1. Validation of a questionnaire to assess niacin-induced cutaneous flushing. Norquist JM; Watson DJ; Yu Q; Paolini JF; McQuarrie K; Santanello NC Curr Med Res Opin; 2007 Jul; 23(7):1549-60. PubMed ID: 17559750 [TBL] [Abstract][Full Text] [Related]
2. Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial. Paolini JF; Mitchel YB; Reyes R; Thompson-Bell S; Yu Q; Lai E; Watson DJ; Norquist JM; Sisk CM; Bays HE Int J Clin Pract; 2008 Jun; 62(6):896-904. PubMed ID: 18410350 [TBL] [Abstract][Full Text] [Related]
3. The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy. Rhodes T; Norquist JM; Sisk CM; McQuarrie K; Trovato A; Liao J; Miller T; Maccubbin D; Watson DJ Int J Clin Pract; 2013 Dec; 67(12):1238-46. PubMed ID: 24102896 [TBL] [Abstract][Full Text] [Related]
4. Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. Kawata AK; Revicki DA; Thakkar R; Jiang P; Krause S; Davidson MH; Punzi HA; Padley RJ Clin Drug Investig; 2009; 29(4):215-29. PubMed ID: 19301936 [TBL] [Abstract][Full Text] [Related]
5. Flushing profile of extended-release niacin/laropiprant at initiation of therapy in Asian lipid clinic patients. Kush D; Hu DY; Ye P; Kim HS; Chen E; Sirah W; McCrary Sisk C; Paolini JF; Maccubbin D Cardiology; 2009; 114(3):192-8. PubMed ID: 19602880 [TBL] [Abstract][Full Text] [Related]
6. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Morgan JM; Capuzzi DM; Guyton JR Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660 [TBL] [Abstract][Full Text] [Related]
7. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324 [TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Grundy SM; Vega GL; McGovern ME; Tulloch BR; Kendall DM; Fitz-Patrick D; Ganda OP; Rosenson RS; Buse JB; Robertson DD; Sheehan JP; Arch Intern Med; 2002 Jul; 162(14):1568-76. PubMed ID: 12123399 [TBL] [Abstract][Full Text] [Related]
9. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Cefali EA; Simmons PD; Stanek EJ; McGovern ME; Kissling CJ Int J Clin Pharmacol Ther; 2007 Feb; 45(2):78-88. PubMed ID: 17323787 [TBL] [Abstract][Full Text] [Related]
10. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation. Cefali EA; Simmons PD; Stanek EJ; Shamp TR Int J Clin Pharmacol Ther; 2006 Dec; 44(12):633-40. PubMed ID: 17190373 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of laropiprant on niacin-induced flushing. Maccubbin DL; Chen F; Anderson JW; Sirah W; McCrary Sisk C; Kher U; Olsson AG; Bays HE; Mitchel YB Am J Cardiol; 2012 Sep; 110(6):817-22. PubMed ID: 22683042 [TBL] [Abstract][Full Text] [Related]
12. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial. Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937 [TBL] [Abstract][Full Text] [Related]
15. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD Arch Intern Med; 2000 Apr; 160(8):1177-84. PubMed ID: 10789612 [TBL] [Abstract][Full Text] [Related]
16. A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. Jacobson TA Mayo Clin Proc; 2010 Apr; 85(4):365-79. PubMed ID: 20360295 [TBL] [Abstract][Full Text] [Related]
17. The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]. Mills E; Prousky J; Raskin G; Gagnier J; Rachlis B; Montori VM; Juurlink D BMC Clin Pharmacol; 2003 Nov; 3():4. PubMed ID: 14614780 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Capuzzi DM; Guyton JR; Morgan JM; Goldberg AC; Kreisberg RA; Brusco OA; Brody J Am J Cardiol; 1998 Dec; 82(12A):74U-81U; discussion 85U-86U. PubMed ID: 9915666 [TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study. Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390 [TBL] [Abstract][Full Text] [Related]
20. Apple pectin for the reduction of niacin-induced flushing. Moriarty PM; Backes J; Dutton JA; He J; Ruisinger JF; Schmelzle K J Clin Lipidol; 2013; 7(2):140-6. PubMed ID: 23415433 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]